Standard bloodwork cannot detect breast cancer. Routine blood panels, including complete blood counts and metabolic panels, were not designed to find cancer and will not flag it. There are, however, specialized blood tests that play a role in breast cancer care, and newer experimental tests are being developed specifically for cancer detection. None of them are currently recommended as a screening tool for people without symptoms.
What Standard Bloodwork Can and Cannot Do
The blood tests your doctor orders at an annual physical measure things like blood cell counts, liver and kidney function, cholesterol, and blood sugar. These tests reveal a lot about your general health, but they don’t look for cancer-specific signals. A normal blood panel result does not mean you’re cancer-free, and an abnormal result doesn’t point to breast cancer specifically.
Even tests designed to look for cancer-related proteins in the blood fall short when it comes to finding breast cancer early. Two well-known tumor markers, CA 15-3 and CEA, have been used in breast cancer care for decades. But their sensitivity and specificity are too low to work as a diagnostic tool. In other words, these markers miss too many cancers and sometimes flag problems that aren’t cancer at all. They’re generally agreed to be unsuitable for primary diagnosis.
How Tumor Markers Are Actually Used
CA 15-3 and a related marker called CA 27.29 are FDA-approved, but only for monitoring people who already have a breast cancer diagnosis. Oncologists use them alongside imaging and physical exams to track whether treatment is working or whether the disease is progressing. Rising levels can signal that cancer is growing or spreading, while falling levels may indicate that treatment is effective.
Elevated levels of these markers before surgery are associated with worse outcomes. In one study published in the British Journal of Cancer, high pre-operative values of both CEA and CA 15-3 were strongly linked to earlier death from disease. But these findings are useful for prognosis in diagnosed patients, not for catching breast cancer in someone who doesn’t know they have it.
For HER2-positive breast cancer specifically, a rising level of circulating HER2 protein in the blood can serve as an early indicator that the disease is progressing. The rise and fall of this marker tends to parallel the clinical course of the disease regardless of what treatment is being used.
Liquid Biopsies: A Different Kind of Blood Test
Liquid biopsy is a newer category of blood test that looks for fragments of tumor DNA circulating in the bloodstream. When cancer cells die, they shed tiny pieces of their DNA into the blood. These fragments, called circulating tumor DNA, carry the same genetic mutations found in the tumor itself. In theory, detecting those fragments could reveal the presence of cancer without a tissue biopsy or imaging scan.
The challenge is that tumor DNA makes up a tiny fraction of the total free-floating DNA in your blood. Over 80% of that circulating DNA comes from normal blood cells, and those cells accumulate their own mutations through aging. Distinguishing true cancer signals from normal background noise is extremely difficult, especially when a tumor is small and shedding very little DNA.
Right now, liquid biopsies are clinically useful mainly in advanced cancer. Guidelines recommend them for identifying specific genetic mutations in metastatic disease, which can help oncologists choose targeted therapies. They are not approved or recommended for screening healthy people.
Multi-Cancer Detection Tests
A new wave of blood tests aims to detect multiple types of cancer at once by analyzing DNA methylation patterns, which are chemical modifications that change how genes behave. In breast cancer, certain tumor suppressor genes get abnormally silenced through a process called hypermethylation, and these patterns can sometimes be detected in blood samples.
The most widely discussed of these is the Galleri test, made by GRAIL. It screens for over 50 cancer types from a single blood draw. However, its sensitivity for early-stage breast cancer is notably poor, detecting fewer than 10 to 16% of stage I breast cancers. For context, that means it would miss the vast majority of early breast cancers, which is exactly when detection matters most.
Another test called CancerSEEK showed roughly 30% overall sensitivity for breast cancer and about 40% for early-stage cancers across all types. These numbers are significantly worse than mammography, which catches around 85% of breast cancers overall. A more experimental approach using circulating tumor cells rather than DNA reported much higher numbers in early studies, with over 90% sensitivity across stages. But these results come from controlled research settings and have not yet been validated in large-scale screening programs.
No multi-cancer early detection test is FDA-approved for breast cancer screening. None appear in the 2024 NCCN breast cancer screening guidelines, which continue to recommend mammography with tomosynthesis, clinical breast exams, and MRI for high-risk individuals as the standard screening tools.
Where Blood Tests Show Real Promise
The strongest case for blood-based testing in breast cancer is monitoring for recurrence and treatment resistance. A large international trial called SERENA-6, involving more than 3,300 patients across 23 countries, used liquid biopsy blood tests to detect a specific treatment-resistance mutation called ESR1 in women with advanced breast cancer. Patients whose blood tests caught this mutation early, before imaging showed any sign of tumor growth, were switched to a new drug. The results showed improved outcomes compared to staying on standard treatment.
This represents a meaningful shift in how blood tests fit into cancer care. Rather than replacing imaging for initial detection, they’re proving useful for catching molecular changes that happen during treatment, changes that are invisible on a scan but detectable in the blood. For breast cancer survivors, serial blood testing could eventually become a practical way to monitor for recurrence, since repeated blood draws are far easier to manage than frequent imaging.
Why Mammography Still Leads
The fundamental problem with using blood tests for early breast cancer detection is biological. Small, early-stage tumors release very little material into the bloodstream. The smaller the cancer, the harder it is to find its signal among normal DNA and proteins circulating in your blood. Mammography, by contrast, can detect structural changes in breast tissue, including tiny calcifications and masses, well before a tumor is large enough to shed detectable amounts of DNA or protein into the bloodstream.
There are no FDA-approved blood tests for the early detection of new or recurrent breast cancer. The American Society of Clinical Oncology recommends using tumor markers like CA 15-3 only in conjunction with imaging and clinical examination, and only for people already diagnosed. For everyone else, mammography remains the single most effective screening tool, and the only one supported by current guidelines.
Cost and Access
Specialized cancer blood tests are expensive. Liquid biopsy panels range from about $500 for a single mutation test to $1,500 or more for comprehensive gene panels. Multi-cancer detection tests like Galleri cost around $949 out of pocket. Most insurance plans do not cover these tests for screening purposes, since they lack the clinical validation and regulatory approval needed for coverage. Some insurers will cover liquid biopsies when ordered for patients with advanced cancer to guide treatment decisions, but coverage varies widely.
If you’re considering one of these tests on your own, keep in mind that a positive result would still require follow-up imaging and likely a tissue biopsy to confirm anything. A negative result, given the low sensitivity for early breast cancer, offers limited reassurance. For most people, the money is better spent ensuring they’re up to date on recommended mammography screening.